Visceral artery pseudoaneurysm: predictive factors for clinical success after transarterial embolization

内脏动脉假性动脉瘤:经动脉栓塞术后临床成功的预测因素

阅读:1

Abstract

BACKGROUND: Visceral artery pseudoaneurysm (VAPA) may result from trauma, operation, infection, inflammation, vasculitis, or malignancy. Factors associated with clinical success transarterial embolization (TAE) of VAPA have never been reported. The aim of this retrospective monocentric study was to describe clinical presentation and outcomes for patients treated for VAPA with TAE, and to identify factors associated with clinical success. METHODS: We retrospectively reviewed data from all patients referred to the University Hospital of Saint-Etienne treated with TAE for VAPA between October 2012 and January 2023. Inclusion criteria included: all patients treated by TAE for VAPA arising from branches of the coeliac trunk, superior mesenteric artery, and renal artery. We considered pre- and per-procedure clinical data, biological data, outcomes, and complications. Post-operative data included early mortality (≤30 days), repeat embolization, and complications. Predictive factors associated with clinical success were evaluated. RESULTS: Our sample included 89 patients (68 males). The median age was 65 [49-74] [median (Q1-Q3)] years, and the median hemoglobin level was 9 (7.6-11) g/dL. On pre-operative computed tomography (CT), active bleeding was detected in 31 (34.8%) patients. Coils were used in 58 (65.2%) procedures. Clinical success was achieved in 77 (86.5%) patients. There were 11 (12.4%) minor complications. Five (5.6%) patients died within the first 30 days. In univariate analysis, hemoglobin levels were associated with clinical success (P=0.027) and number of red blood cell (RBC) transfusions (P=0.007) and gastrointestinal bleedings (P=0.005) were associated with clinical failure. No factors were statistically significant in multivariate analysis. CONCLUSIONS: Low hemoglobin levels, high numbers of RBC transfusions, and gastrointestinal bleedings were associated with clinical failure after TAE for VAPA. Multicentre studies are needed to investigate further.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。